Microcide Signs Research Collaboration

Microcide Pharmaceuticals, Inc. has entered into a research collaborative agreement with Discovery Partners International, Inc., to optimise the drug-like qualities of Microcide’s recently discovered broad-spectrum antifungal compound series. Using Microcide’s proprietary microbial genomics VALID System, the Company has discovered and developed a series of promising antifungal compounds to the point of lead optimisation. Members of Read more about Microcide Signs Research Collaboration[…]

IVAX Acquires Drug In Advanced Clinical Development

IVAX Corporation has entered into an exclusive agreement with Eli Lilly and Company to develop and market the AMPA receptor antagonist, talampanel, worldwide. Phase II clinical trials with talampanel in patients with severe epilepsy not responsive to other drugs have shown positive results and phase III trials in epilepsy will be done to confirm and Read more about IVAX Acquires Drug In Advanced Clinical Development[…]

Schering And MediGene Collaborate On Human Papilloma Virus Treatment

Schering AG and MediGene AG has announced the formation of a world-wide strategic alliance to develop and commercialise MediGene’s Viral Vaccine for the treatment of precancerous lesions of the cervix caused by human papilloma viruses (HPV). Schering has been granted a world-wide exclusive license with the right to grant sublicenses. MediGene has an option for Read more about Schering And MediGene Collaborate On Human Papilloma Virus Treatment[…]

Dow To Acquire Collaborative BioAlliance

The Dow Chemical Company has signed a definitive agreement to purchase The Collaborative Group’s Biotechnology Services Division, including all of the assets of Collaborative BioAlliance, Inc. (CBA) and Collaborative Smithfield Corp. Pending regulatory review and obtaining certain third-party consents, the acquisition is expected to close towards the end of November. The financial terms of the Read more about Dow To Acquire Collaborative BioAlliance[…]

AHP And Aventis Pharma Finalise HRT Agreement

American Home Products Corporation and Aventis Pharma have renegotiated their licensing agreement for trimegestone, a modern progestational molecule originated by Aventis for hormone replacement therapy. Under the new agreement, Wyeth-Ayerst Laboratories, the pharmaceutical division of AHP, has exclusive development and worldwide marketing rights for trimegestone for all indications and formulations except transdermal products. The rights Read more about AHP And Aventis Pharma Finalise HRT Agreement[…]

FDA Grants Fast Track Designation For Secretin

Repligen Corporation announced that the U.S. FDA has granted Fast Track designation for secretin for the treatment of pediatric autism. “We are very pleased that the FDA has designated this program for Fast Track status,” stated Walter C. Herlihy, President and CEO of Repligen Corporation. “We believe that this action affirms a heightened awareness to Read more about FDA Grants Fast Track Designation For Secretin[…]

New Treatment Option Approved For Lennox-Gastaut Syndrome

The U.S. FDA has approved Topamax (topiramate) tablets and sprinkle capsules as an adjunctive (add-on) treatment for adults and children (age 2-16) suffering from seizures associated with Lennox-Gastaut Syndrome (LGS) is one of the most severe forms of epilepsy. Individuals who suffer from this illness experience dozens of seizures a day, many of which are Read more about New Treatment Option Approved For Lennox-Gastaut Syndrome[…]

FDA Approves Progestin Contraceptive Yasmin

Berlex Laboratories has announced FDA approval of their new low-dose, monophasic oral contraceptive, the first to contain the unique progestin, drospirenone. Drospirenone is different from the progestins currently available in other oral contraceptives. As an analogue of spironolactone, which is widely used by Ob/Gyns for many women, drospirenone exhibits antimineralocorticoid activity which influences the regulation Read more about FDA Approves Progestin Contraceptive Yasmin[…]

Dr. Reddy’s And PRI Sign Co-Marketing Agreement

Pharmaceutical Resources, Inc. (PRI) has entered into a broad-based co-marketing and development agreement with Dr. Reddy’s Laboratories (Reddy).The agreement covers fourteen drugs to be marketed through PRI’s primary operating subsidiary, Par Pharmaceutical, Inc., (Par). Abbreviated new drug applications for six of the drugs have been filed with the FDA and are pending approval. Through PRI’s Read more about Dr. Reddy’s And PRI Sign Co-Marketing Agreement[…]

Millennium And Lilly Extend Collaboration

Millennium Pharmaceuticals, Inc. and Eli Lilly and Company have announced a one-year extension of their cardiovascular disease research collaboration. The five-year partnership, originally due to expire in October, will continue at full capacity at least through October of 2001, at which time Lilly has the option to extend for up to two additional years. Since Read more about Millennium And Lilly Extend Collaboration[…]